Form 4: Marinus Pharmaceuticals' Chief Medical Officer Hulihan Sells Shares to Cover Tax Obligations

Chief Medical Officer of Marinus Pharmaceuticals, Joseph Hulihan, sold 4,828 shares of common stock on August 5, 2024, to cover tax obligations related to vesting restricted stock units.

Summary

• Joseph Hulihan, the Chief Medical Officer of Marinus Pharmaceuticals, sold 4,828 shares of common stock on August 5, 2024.
• The sale was executed at a weighted-average price of $1.13 per share, with individual transactions ranging from $1.11 to $1.15.
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on May 16, 2022.
• The purpose of the sale was to cover tax obligations associated with the vesting of restricted stock units.
• Following the transaction, Hulihan directly owns 72,725 shares of Marinus Pharmaceuticals' common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine stock sale by an insider for tax purposes. It doesn't inherently convey positive or negative sentiment about the company's prospects.

Industry Context

Sales by company insiders are a common occurrence and are often related to personal financial planning, such as covering tax obligations. The use of a 10b5-1 plan suggests the insider planned the transaction in advance to avoid accusations of trading on inside information.

Stakeholder Impact

• The sale of shares by a company officer could be perceived negatively by some shareholders, although the use of a 10b5-1 plan mitigates concerns about insider trading.
• The impact on other stakeholders (employees, customers, suppliers, creditors) is likely minimal.

Key Dates

Keywords

Marinus Pharmaceuticals, MRNS, Joseph Hulihan, Chief Medical Officer, Form 4, Stock Sale, Rule 10b5-1 Plan, Tax Obligations, Restricted Stock Units, Insider Trading